YEEHAW CANDIDATES | Stock Discussion Forums

SiliconInvestor

register

Strategies & Market Trends | YEEHAW CANDIDATES

Previous 10 | Next 10

To: Galirayo who wrote (20084)	11/5/2006 10:47:23 AM
From: Ken W	of 23958

Ray 8 days to cover is simply calulated, as you said, by average volume per day. Most of the current short position could be covered in 1 day with large volume. It depends a great deal on who is short...if retail is the culpert then I'd expect a shorter time frame higher volume cover. Professional instiututional trading desks get a little less flustered and use upside stops to take them out the same way that we set stops to the downside to protect profit or capital. IF it is strictly market maker firms that are short then there will be no spike as they will keep the stock under pressure all the while covering their naked position with little effect on the stock price..This happens particularly in thinly traded stocks...you know, where the ask size is showing 1k shares and 5k blocks are going thru at the ask with no bump... Ken

Share	Recommend \| Keep \| Reply \| Mark as Last Read \| Read Replies (1)

To: J.F. who wrote (20059)	11/6/2006 8:16:28 AM
From: ACAN	of 23958

jf; [XOMA] in play XOMA Receives European Certification to Manufacture Investigational Medicinal Products Monday November 6, 3:10 am ET BERKELEY, Calif., Nov. 6, 2006 (PRIMEZONE) -- XOMA Ltd. (NASDAQ:XOMA - News) today announced that its cGMP pharmaceutical manufacturing facilities have received Investigational Medicinal Products certification from the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom. The MHRA certification approves XOMA's manufacturing facilities for the production of biological investigational medicinal products to be used in clinical trials in the European Union. Allan

Share	Recommend \| Keep \| Reply \| Mark as Last Read \| Read Replies (2)

To: Galirayo who wrote (19487)	11/6/2006 9:07:06 AM
From: ACAN	of 23958

Ray; [GILT] Gilat Reports Fourth Consecutive Quarter of Improved Financial Results in Q3 2006 Monday November 6, 8:17 am ET PETAH TIKVA, Israel--(BUSINESS WIRE)--Gilat Satellite Networks Ltd. (Nasdaq: GILT - News), a worldwide leader in satellite networking technology, solutions and services, today reported its results for the quarter ending September 30, 2006. Highlights for the Quarter: Revenues increased to $63.8 million, representing a 30% year-over-year growth; Net income increased to $2.7 million, from a net loss of $1.7 million in 3Q2005; Positive cash flow of $15 million Shareholders' equity increased by $72.6 million, long term debt decreased by $71.7 million, mainly due to York's loan conversion Allan

Share	Recommend \| Keep \| Reply \| Mark as Last Read

To: J.F. who wrote (20092)	11/6/2006 9:14:57 AM
From: Galirayo	of 23958

Generex Biotechnology to Begin the First Human Clinical Trial of Avian Influenza Vaccine Monday November 6, 9:10 am ET Company Signs Agreement With the Lebanese-Canadian Hospital in Beirut as a Site for Trials TORONTO--(MARKET WIRE)--Nov 6, 2006 -- Generex Biotechnology Corporation (NASDAQ:GNBT - News) announced today that it has entered into an agreement with the Lebanese-Canadian Hospital in Beirut, Lebanon to conduct a human clinical trial of the Antigen Express synthetic avian influenza vaccine, representing the first studies to be conducted in man. The study is being undertaken with the approval of the appropriate Lebanese governmental and regulatory bodies. Antigen Express, Inc., a wholly owned subsidiary of Generex, designed the vaccine using its proprietary platform technology and has been conducting pre-clinical studies since 2004. Dr. Alexander Abdelnoor, Department of Microbiology & Immunology, Faculty of Medicine, American University of Beirut, will also be participating as a consultant for the trials. The vaccine being developed by Antigen Express is based upon simple peptide-synthesis technology and can thus be manufactured rapidly, easily, and at inexpensive cost. This is in sharp contrast to traditional egg-based vaccines that rely on biological systems for vaccine production, making their availability to at-risk populations during a pandemic extremely limited. The preclinical studies conducted with the synthetic vaccine suggest that it may be used with more traditional vaccines to extend their utility as well as to prevent mortality associated with H5N1 infection when used alone. The Antigen Express vaccine consists of specific fragments of the H5 protein from the H5N1 influenza virus that have been modified to enhance their potency in stimulating CD4+ T helper cells. Flu specific T helper cells have been shown to be essential in the development of a robust, protective immune response against influenza. The methods for enhancing the immune stimulating potency of the fragments were developed by Dr. Robert Humphreys, founder of Antigen Express. In brief, specific fragments of the H5 protein are identified (antigenic epitopes) that have the potential to interact with MHC class II molecules. The ability of CD4+ T helper cells to become stimulated to recognize specific proteins depends upon the presentation of epitopes derived from that protein to CD4+ cells by MHC class II molecules. Based upon an understanding of MHC class II charging by antigenic epitopes, Antigen Express scientists have developed proprietary methods for increasing the vaccine potency of antigenic peptides. A similar synthetic peptide vaccine designed by the same methods targeting a tumor-associated protein (encoded by HER-2/neu) has been in the clinic for more than a year at the Walter Reed Army Medical Center (WRAMC). That compound has shown good activity in the antigen-specific stimulation of CD4+ T helper cells. "The trials in Lebanon will complement nicely the studies planned for the US," said Dr. Eric von Hofe, President of Antigen Express. "We know that bird flu is a threat that shows no signs of going away soon. Coupled with the lack of any widely available vaccine, it is paramount to begin testing the synthetic vaccine being developed at Antigen Express as rapidly as possible."

Share	Recommend \| Keep \| Reply \| Mark as Last Read

From: Joseph B. Schmidt	11/6/2006 9:21:38 AM
	of 23958

SPDE news today; also, go to speedus.com about their upcoming trial in February w/ AT&T... Zargis Awarded U.S. Army Contract Nov 6, 2006 8:00:00 AM PRINCETON, N.J., Nov. 6 /PRNewswire/ -- Zargis Medical Corp., a spin-off from Siemens Corporate Research (NYSE: SI) and a majority-owned subsidiary of Speedus Corp. (Nasdaq: SPDE), today announced that it has been awarded a $101,000 contract by the U.S. Army to develop pilot-versions of a telemedicine system for use in cardiology. Under the terms of the contract, Zargis will develop prototypes of a system designed to record, synchronize and analyze heart sounds, lung sounds and ECG signals in pediatric patients who are being cared for by remote military treatment facilities. The system will be fully integrated with an existing Army telehealth platform. "We're very pleased that Zargis has been selected to enhance the Army's telehealth platform," stated Zargis CEO John Kallassy. "This project builds upon our expertise in computer-aided auscultation and we expect it to result in additional opportunities for Zargis involving military and civilian telemedicine initiatives." About Zargis Medical Corp. Zargis Medical Corp. develops advanced diagnostic decision support products and services for primary care physicians, pediatricians, cardiologists and other healthcare professionals. Zargis was formed in 2001 when Siemens Corporate Research, a division of Siemens AG (NYSE: SI), and Speedus Corp. co-invested to develop and market an advanced acoustic technology designed to detect heart abnormalities identified through analysis of heart sounds. About Cardioscan(R) Zargis has developed Cardioscan, the first and only computer-assisted medical device designed to support physicians in analyzing heart sounds for the identification of suspected systolic and diastolic murmurs. Cardioscan is a non-invasive device that is easy to use, portable, and takes just minutes to perform. The device implements voice-guided protocol and a graphical user interface while maintaining an efficient physician workflow. Cardioscan provides a summary of findings in terms that are readily understood by physicians and offers an additional range of quantitative auscultatory information that cannot be obtained through listening alone. As a result, Cardioscan enhances auscultation-a procedure that has been universally employed through a stethoscope for nearly two-hundred years. For additional information about Zargis or Speedus Corp., contact Peter Hodge at 888.773.3669 (ext. 23) or phodge@zargis.com or visit the following Web sites: zargis.com and speedus.com. Statements contained herein that are not historical facts, including but not limited to statements about the Company's product, corporate identity and focus, may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company, including, but not limited to, the continuing development of the Company's sales, marketing and support efforts. SOURCE Zargis Medical Corp. ---------------------------------------------- Peter Hodge of Zargis Medical Corp. 1-888-773-3669 ext. 23 phodge@zargis.com

Share	Recommend \| Keep \| Reply \| Mark as Last Read

Previous 10 | Next 10

Copyright/IP Policy

Copyright © 1995-2013 Knight Sac Media. All rights reserved.